Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Hepatology Actions . 2021 Jan;73(1):68-78. doi: 10.1002/hep.31267. Epub 2020 Nov 6. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta

2021 EvidenceUpdates

2. Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure

Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Gastroenterol Actions . 2020 Oct 13. doi: 10.1097/MCG.0000000000001450. Online ahead of print. Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure , , , , , , , , , , , Affiliations Expand

2021 EvidenceUpdates

3. Hepatitis B surface antigen (Heplisav B) - Hepatitis B vaccine

Hepatitis B surface antigen (Heplisav B) - Hepatitis B vaccine Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/27931/2021 EMEA/H/C/005063 Heplisav B (hepatitis B vaccine (...) (recombinant, adjuvanted)) An overview of Heplisav B and why it is authorised in the EU What is Heplisav B and what is it used for? Heplisav B is a vaccine for preventing hepatitis B virus infection in adults. It is also likely to prevent infection with the hepatitis D virus as this virus is only present in people with hepatitis B infection. Heplisav B is used in accordance with official recommendations. It contains a protein from the hepatitis B virus. How is Heplisav B used? Heplisav B is given as two

2021 European Medicines Agency - EPARs

4. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial

Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Am J Gastroenterol Actions . 2020 Nov;115(11):1802-1811. doi: 10.14309/ajg.0000000000000926. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients

2021 EvidenceUpdates

5. What is the evidence for cost-effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK?

What is the evidence for cost-effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK? Knowledge & Library Services (KLS) Evidence Briefing What is the evidence for cost-effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK? Jennifer Ford 22nd January 2021 What is the evidence for cost-effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK (...) ? KLS Evidence Briefing 22nd January 2021 Question This briefing summarises the evidence on the cost- effectiveness of testing for HIV, Hepatitis B and Hepatitis C in primary care and other settings in the UK, up to 3 rd December 2020 (no date limits were applied to the literature searches on which this briefing is based, and searches were conducted on 3 rd December 2020). Key messages • There are primary research studies providing evidence on cost-effectiveness of testing for HIV, Hepatitis B

2021 Public Health England - Evidence Briefings

6. Givosiran (Givlaari) - for the treatment of acute hepatic porphyria

Givosiran (Givlaari) - for the treatment of acute hepatic porphyria Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after

2021 Health Canada - Drug and Health Product Register

7. Hepatitis B: antenatal screening and selective neonatal immunisation pathway

Hepatitis B: antenatal screening and selective neonatal immunisation pathway Hepatitis B: antenatal screening and selective neonatal immunisation pathway - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check how (...) the new rules affect you Guidance Hepatitis B: antenatal screening and selective neonatal immunisation pathway Guidance on the delivery of antenatal screening and selective neonatal immunisation services for pregnant women living with hepatitis B and their babies. Published 8 January 2021 From: Documents Ref: PHE publications gateway number: GW-1799 HTML Ref: PHE publications gateway number: GW-1799 PDF , 3.16MB , 72 pages This file may not be suitable for users of assistive technology. Request

2021 Public Health England

8. Screening for Hepatitis B Virus Infection in Adolescents and Adults

Screening for Hepatitis B Virus Infection in Adolescents and Adults Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Persons at High Risk for Infection The USPSTF recommends screening for hepatitis B virus (HBV) infection in persons at high risk for infection. B View the Clinical Summary in Population Asymptomatic, nonpregnant (...) adolescents and adults at high risk for hepatitis B virus (HBV) infection (including those at high risk who were vaccinated before being screened for HBV infection). Recommendation Screen persons at high risk for HBV infection. Grade: B Risk Assessment Important risk groups for HBV infection with a prevalence of ≥2% that should be screened include: Persons born in countries and regions with a high prevalence of HBV infection (≥2%) U.S.-born persons not vaccinated as infants whose parents were born

2020 U.S. Preventive Services Task Force

9. Sofosbuvir (Sovaldi) - treatment of chronic hepatitis C (CHC)

Sofosbuvir (Sovaldi) - treatment of chronic hepatitis C (CHC) Sofosbuvir (Sovaldi ® ) multiple formulations Gilead Sciences Ltd November 2020 Advice context: The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intends to publish final technology (...) of the marketing authorisation, sofosbuvir (Sovaldi ® ) cannot be endorsed within NHS Wales for use in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in paediatric patients aged 3 to < 12 years.

2020 All Wales Medicines Strategy Group

10. Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese Multi-institutional Randomized Controlled Trial (ND-trial)

Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese Multi-institutional Randomized Controlled Trial (ND-trial) Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese Multi-institutional Randomized Controlled Trial (ND-trial) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation Ann Surg Actions . 2020 Jun 23. doi: 10.1097/SLA.0000000000004051. Online ahead of print. Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese Multi-institutional Randomized Controlled Trial (ND-trial) , , , , , , , , , , Affiliations Expand Affiliation 1 *Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan †Center for Data Science, Yokohama City

2020 EvidenceUpdates

11. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians

World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your password? Enter your email address below and we will send you the reset instructions Email (...) States, the incidence of hepatitis C virus (HCV) infection is 1.2 per 100 000 persons, the prevalence is 2.4 million cases, and annual mortality is more than 15 000 deaths ( , ). Eliminating hepatitis will require diagnosis of 90% of those infected followed by treatment of 80% of those diagnosed ( ). The World Health Organization (WHO) updated its evidence-based guideline on chronic HCV infection in July 2018 ( ) ( ). Although the WHO guideline is primarily targeted toward policymakers in low

2020 American College of Physicians

12. Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of RCTs Full Text available with Trip Pro

Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of RCTs Redirecting

2020 JHEP Reports

13. Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis Full Text available with Trip Pro

Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis Yandi Xie, Rui Jin, Guangjun Song, Hui Ma, Bo Feng Yandi Xie Peking University People's Hospital ORCiD: https://orcid.org/0000-0001-5002-341X Rui Jin Peking University People's Hospital Guangjun Song Peking University People's Hospital Hui Ma

2020 Research Square

14. Comparison of effectiveness on interventional therapies for unresectable hepatic cancer- a network meta-analysis Full Text available with Trip Pro

Comparison of effectiveness on interventional therapies for unresectable hepatic cancer- a network meta-analysis Inplasy Protocol 758 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

15. Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis Full Text available with Trip Pro

Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis Inplasy Protocol 755 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

16. Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis > > > Article Full Text Original Article OPEN ACCESS Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis Hong-Qin Xu 1 , Chun-Guang Wang 2 , Peng Xiao 1 and Yan-Hang Gao *,1 Author (...) Background and Aims: Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy (sustained virologic response rates at 12 weeks’ after treatment [referred to as SVR12]) and safety. Methods: Data from 21 phase III clinical trials were analyzed. Results

2020 Journal of clinical and translational hepatology

17. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Copyright © ESPGHAN and NASPGHAN (...) . All rights reserved. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Daniel H. Leung, y James E. Squires, z Ravi Jhaveri, § Nanda Kerkar, jj Chuan-Hao Lin, Parvathi Mohan, # Karen F. Murray, Regino P. Gonzalez-Peralta, yy Eve A. Roberts, and zz Shikha S. Sundaram ABSTRACT In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identi?ed the hepatitis C virus (HCV

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

18. Hepatitis C Virus. (Abstract)

Hepatitis C Virus. Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States, chronically affecting approximately 2.4 million Americans, most of whom are unaware of the infection. Highly effective, well-tolerated therapies are now available with markedly simplified treatment algorithms. Eradication of HCV is a national goal. Increased efforts to extend access to treatment to populations that traditionally are difficult to treat, such as persons who inject drugs

2020 Annals of Internal Medicine

19. Hepatitis B virus persistence and reactivation. Full Text available with Trip Pro

Hepatitis B virus persistence and reactivation. Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications. Individuals ever infected with HBV are at risk of viral reactivation under certain circumstances. This review summarizes studies on HBV persistence and reactivation with a focus on the definitions and mechanisms. Emphasis is placed on the interplay between HBV replication and host immunity as this interplay determines the patterns of persistence following

2020 BMJ

20. Retention enema with Traditional Chinese Medicine for hepatic encephalopathy: A protocol for a systematic review and meta-analysis Full Text available with Trip Pro

Retention enema with Traditional Chinese Medicine for hepatic encephalopathy: A protocol for a systematic review and meta-analysis Inplasy Protocol 705 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols